Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

Relmada Therapeutics Stock Soars on Phase 2 Depression Study Results

Shares of Relmada Therapeutics have traded wildly today after it announced Phase 2 results for its anti-depressant drug dextromethadone. The firm's shares have traded 100–200% higher today and the stock was halted several times trading due to extreme price volatility. ...
Streetwise Reports | October 16, 2019 |

Novamind Selected by Merck to Advance Research for Treatment-Resistant Depression

Novamind’s subsidiary, Cedar Clinical Research, to serve as a key clinical research site Independent validation of the expertise and capabilities of Novamind in managing clinical trials Adds to established track record conducting research a...
Featured Submission | March 18, 2021 |

A Psychedelic & Nutraceutical Opportunity: A Boost for the Brain and Your Portfolio

A psilocybin mushroom, also known as a magic mushroom, offers infinite medical and scientific potential…from cognitive flexibility to potentially addressing clinical depression and eating disorders. There’s a lot we still don’t kn...
Dave Jackson | September 18, 2020 |

Masochism and the Average Gold Investor

Masochism and the Average Gold Investor Source: Michael J. Ballanger for Streetwise Reports 04/22/2019 Sector expert Michael Ballanger discusses generational attitudes toward investing and how they are affecting the precious metals markets. Masochism: "...
Streetwise Reports | April 23, 2019 |

The Inflation–Deflation Conundrum

As I sit here on the shores of lovely Lake Scugog, its weed-infested waters lying in wait for countless unsuspecting propellers soon to be ensnared, I am reminded of the failed world of central banking and policy initiatives, which too has become ensnared in flora of its ...
Streetwise Reports | May 27, 2020 |

Axsome Therapeutics Investors Awaken to Positive Outcome in Phase 2 Narcolepsy Trial

Axsome Therapeutics shares traded 14% higher today after the company reported that its narcolepsy drug candidate AXS-12 achieved its primary endpoint in the Phase 2 CONCERT Study. This morning before U.S. markets opened, clinical-stage biopharmaceutical company Axsom...
Streetwise Reports | December 4, 2019 |

The New Cannabis & CBD Therapy for PTSD

This podcast is part of our StockTalk Cannabis Sector CEO interview series, and our mission going forward is to help listeners and investors understand more about investment opportunities in the public cannabis marketplace. There are around eight million people in the U...
Stockhouse Media | November 6, 2019 |

Feb 28th 2020, Silver Chartbook – The weakest link

The weakest link The weakest link is you . That is not always easy to admit, but it is factual, that the main cause for large draw downs is human error. The list of errors in market participation is long. For example running stops or sitting frozen behind the monitor ...
Korbinian Koller | February 28, 2020 |

Mar 27th 2020, Silver Chartbook – Brace yourself

Brace yourself Right now you might find yourself in this first moment of catching a breath. You might have started getting used to a work from home. In addition, you might be feeling more prepared having stacked up on essentials. Maybe you even got used to this new wo...
Korbinian Koller | March 27, 2020 |

Buzz on the Bullboards: Fail to the chief

It has been an unprecedented week, as focus on major stories related to the financial sector’s struggles and the volatility among crude stocks after OPEC+ said it was slashing output by 1.16 million barrels per day. All eyes were on former President Donald...
Jonathon Brown | April 6, 2023 |
1 2 3 4